Category - News

Developments

iBio making progress with its COVID-19 vaccine candidates

iBio (NYSE AMERICAN:IBIO) reported progress toward developing vaccine candidates for SARS-CoV-2, the coronavirus that causes COVID-19. In a matter of a few weeks, the company used its FastPharming system to create SARS...

March 18, 2020

Markets

Stifel cuts DBV Technologies to hold; PT to $6 from $18

Stifel downgraded DBV Technologies (NASDAQ:DBVT) to “hold” from “buy” and slashed its price target to $6 from $18 after the FDA raised questions about DBV’s Viaskin Peanut’s efficacy, including the impact of patch...

March 17, 2020

Markets

Ladenburg lowers Allena Pharma PT to $13 from $23

Ladenburg Thalmann lowered its price target for Allena Pharmaceuticals (NASDAQ:ALNA) to $13 from $23 largely driven by an increase in the number of shares outstanding, assuming an equity financing. The stock closed at...

March 17, 2020

Markets

Echelon rates Correvio Pharma “tender” after takeover bid from ADVANZ Pharma

Echelon Wealth Partners moved its rating for Correvio Pharma (NASDAQ, TSX:CORV) to “tender” from “hold” after ADVANZ Pharma (TSX:ADVZ) agreed to acquire Correvio, which closed at 35 cents on March 17. Analyst Doug Loe...

March 17, 2020

Markets

SVB Leerink trims Mallinckrodt PT to $2 from $5

SVB Leerink lowered its price target for Mallinckrodt (NYSE:MNK) to $2 from $5, citing a number of changes to its model. The stock closed at $1.80 on March 16. Analyst Ami Fadia writes that her updated model reflects...

March 17, 2020

Markets

SVB Leerink starts Adverum Biotechnologies at OP; PT $17

SVB Leerink launched coverage of Adverum Biotechnologies (NASDAQ:ADVM) with an “outperform” rating and $17 price target. The stock closed at $10.33 on March 13. Adverum’s lead asset, ADVM-022, is in a Phase 1 trial as a...

March 16, 2020

Markets

BTIG cuts Senseonics to neutral; removes PT

BTIG downgraded Senseonics Holdings (NYSE American:SENS) to “neutral” from “buy” and removed its price target after the company released 2020 sales guidance of $15-million to $20-million, well below the Street’s $37...

March 13, 2020

Markets

SVB Leerink cuts Rubius Therapeutics to MP; TP to $4 from $19

SVB Leerink downgraded Rubius Therapeutics (NASDAQ:RUBY) to “market perform” from “outperform” and slashed its price target to $4 from $19 after the company discontinued development of RTX-134 for the treatment of...

March 13, 2020

Markets

BTIG cuts ViewRay to neutral and removes PT

BTIG downgraded ViewRay (NASDAQ:VRAY) to “neutral” from “buy” and removed its price target after the company’s 2020 revenue guidance of $58-million to $95-million was “well below even the lowest Street estimates.” The...

March 13, 2020

Executive Moves

iBio appoints accomplished life sciences executive, Thomas Isett, as co-chairman and CEO

Thomas Isett iBio (NYSE AMERICAN:IBIO) appointed Thomas Isett, a current iBio board member, as its co-chairman and CEO. Mr. Isett succeeds Robert Kay, who has retired from the role of CEO, but will remain as co-chairman...

March 12, 2020

Category - News

iBio making progress with its COVID-19 vaccine candidates

Stifel cuts DBV Technologies to hold; PT to $6 from $18

Ladenburg lowers Allena Pharma PT to $13 from $23

Echelon rates Correvio Pharma “tender” after takeover bid from ADVANZ Pharma

SVB Leerink trims Mallinckrodt PT to $2 from $5

SVB Leerink starts Adverum Biotechnologies at OP; PT $17

BTIG cuts Senseonics to neutral; removes PT

SVB Leerink cuts Rubius Therapeutics to MP; TP to $4 from $19

BTIG cuts ViewRay to neutral and removes PT

iBio appoints accomplished life sciences executive, Thomas Isett, as co-chairman and CEO

General

More